アルツハイマー病向け疾患修飾治療の世界市場

Report Highlights

This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.

Report Includes

• Analysis of the current and future global market for disease-modifying therapies for Alzheimer’s disease (AD)
• Analyses of the global market trends, with market revenue data (sales figures) from 2023 to 2025, forecasts for 2026, and projected CAGRs through 2030
• Estimates of the market’s size and revenue prospects for the global market, accompanied by a market share analysis based on target type, drug type, drug molecule type, and region
• Facts and figures pertaining to market dynamics, technological advancements, regulations, prospects, and the impacts of macroeconomic variables
• Discussion of the underlying opportunities and potential in the disease-modifying therapies market
• Information on products currently available for the diagnosis and treatment of Alzheimer’s, as well as the promising new drug candidates and diagnostic imaging agents
• Review of key marketed products, clinical trials, competitive scenario and R&D activities
• An analysis of emerging trends and the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of the leading companies

Report Scope

Currently, the disease-modifying therapies (DMTs) market for Alzheimer’s disease (AD) is in its early stage of development, as the first DMT for AD (lecanemab) was granted full approval by the U.S. FDA in July 2023. Several DMTs are in late-stage (phase 2 and above) clinical trials. If approved, they can expand the AD DMTs market significantly. BCC Research estimates market data for 2024 (the base year) and forecasts values for 2025 through 2030. Other than the approved products, the revenue forecast also considers the potential therapeutic candidates expected to enter during the forecast period and their targeted market potential.

The report analyzes the AD DMTs market by target type (anti-amyloid and other emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, the Middle East, and Africa).

Table of Contents

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Alzheimer’s Disease Overview
Alzheimer’s Disease Pathophysiology
Pharmaceutical Treatment of AD

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Drivers
High Unmet Need in AD Treatment
Use of Biomarkers to Accelerate AD DMTs Approvals
Challenges
High Failure Rate in AD Drug Development
High Cost and Side Effects of Approved DMTs
Opportunity
DMTs for the Preclinical-Stage of AD

Chapter 4 Regulatory Landscape

U.S.
Standard Drug Approval Process
Expedited Approval Pathways
DMTs Approval Status by Country/ Region

Chapter 5 Emerging Technologies and Developments

A Multi-target Therapeutic Framework
Blood Tests for AD Screening and Diagnosis
Pipeline Analysis
Key Takeaways:
Small Molecule DMTs in Phase 3 Clinical Trials
Large Molecule DMTs in Phase 3 Clinical Trials

Chapter 6 Market Segment Analysis

Segmentation Breakdown
Market Analysis, by Target Type
Anti-Amyloid
Other Emerging Alzheimer’s Pathology Targets for DMTs
Market Analysis, by Drug
Market Analysis, by Drug Molecule Type
Large Molecule
Small-Molecule
Geographic Breakdown
Market Analysis by Region
North America
Asia-Pacific
Europe
Middle East and Africa
South America

Chapter 7 Competitive Intelligence

Overview
Notable Companies Developing AD DMTs
Recent Developments/Strategic Analysis

Chapter 8 Appendix

Methodology
References
Abbreviations
Company Profiles
ALZHEON INC.
ANAVEX LIFE SCIENCES CORP.
ANNOVIS BIO INC.
BIOGEN
BIOVIE INC.
EISAI CO. LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
NOVO NORDISK A/S
TAURX PHARMACEUTICALS LTD.

List of Tables

Summary Table : Global Market for DMTs for AD, by Region, Through 2030
Table 1 : Key Biomarkers Commonly Used to Evaluate and Support the Clinical Significance of AD DMTs
Table 2 : Recent Late-Stage Therapeutic Candidates Failures in Clinical Trials, 2025
Table 3 : DMTs Approval Status, by Country or Region, 2025
Table 4 : Selected Blood Tests in Development for AD Screening/Diagnosis
Table 5 : Disease-Modifying Small Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 6 : Disease-Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 7 : Global Market for DMTs for AD, by Target Type, Through 2030
Table 8 : Commercially Available Anti-Amyloid Drugs
Table 9 : Global Market for DMTs for AD, by Drug, Through 2030
Table 10 : Small Molecule versus Large Molecule Drugs
Table 11 : Global Market for DMTs for AD, by Drug Molecule Type, Through 2030
Table 12 : Global Market for DMTs for AD, by Region, Through 2030
Table 13 : Notable Companies Developing AD DMTs, 2025
Table 14 : Abbreviations Used in the Report
Table 15 : Alzheon Inc.: Company Snapshot
Table 16 : Alzheon Inc.: Product Portfolio
Table 17 : Alzheon Inc.: News/Key Developments, 2024
Table 18 : Anavex Life Sciences Corp.: Company Snapshot
Table 19 : Anavex Life Sciences Corp.: Financial Performance, FY 2023 and 2024
Table 20 : Anavex Life Sciences Corp.: Product Portfolio
Table 21 : Anavex Life Sciences Corp.: News/Key Developments, 2024
Table 22 : Annovis Bio Inc.: Company Snapshot
Table 23 : Annovis Bio Inc.: Financial Performance, FY 2023 and 2024
Table 24 : Annovis Bio Inc.: Product Portfolio
Table 25 : Biogen: Company Snapshot
Table 26 : Biogen: Financial Performance, FY 2023 and 2024
Table 27 : Biogen: Product Portfolio
Table 28 : Biogen: News/Key Developments, 2024 and 2025
Table 29 : BioVie Inc.: Company Snapshot
Table 30 : BioVie Inc.: Financial Performance, FY 2022 and 2023
Table 31 : BioVie Inc.: Product Portfolio
Table 32 : Eisai Co. Ltd.: Company Snapshot
Table 33 : Eisai Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 34 : Eisai Co. Ltd.: Product Portfolio
Table 35 : Eisai Co. Ltd.: News/Key Developments, 2023–2025
Table 36 : Johnson & Johnson Services Inc.: Company Snapshot
Table 37 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 38 : Johnson & Johnson Services Inc.: Product Portfolio
Table 39 : Johnson & Johnson Services Inc.: News/Key Developments, 2024
Table 40 : Lilly: Company Snapshot
Table 41 : Lilly: Financial Performance, FY 2023 and 2024
Table 42 : Lilly: Product Portfolio
Table 43 : Lilly: News/Key Developments, 2024
Table 44 : Novo Nordisk A/S: Company Snapshot
Table 45 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 46 : Novo Nordisk A/S: Product Portfolio
Table 47 : TauRx Pharmaceuticals Ltd.: Company Snapshot
Table 48 : TauRx Pharmaceuticals Ltd.: Product Portfolio
Table 49 : TauRx Pharmaceuticals Ltd.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Market Shares for DMTs for AD, by Region, 2024
Figure 1 : Disease-Modifying Therapies (DMTs) Market Snapshot for Alzheimer’s Disease
Figure 2 : People Living with Dementia Around the World, 2020-2050
Figure 3 : Global Market Shares of DMTs for AD, by Region, 2024
Figure 4 : Global Market Shares of DMTs for AD, by Leading Companies, 2024
Figure 5 : Biogen: Revenue Shares, by Business Unit, FY 2024
Figure 6 : Biogen: Revenue Shares, by Country/Region, FY 2024
Figure 7 : Eisai Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 8 : Eisai Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 9 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 10 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 11 : Lilly: Revenue Shares, by Business Unit, FY 2024
Figure 12 : Lilly: Revenue Shares, by Country/Region, FY 2024
Figure 13 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2024
Figure 14 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2024

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
• 免疫療法薬の世界市場 2025-11-12
• 農業におけるAIの世界市場 2025-11-10
• 固体酸化物形燃料電池の技術と世界市場 2025-11-07
• 世界の電気アーク炉市場 2025-11-07

BCC Research  出版レポート一覧